Max Lerchenberger

536 citations
7 papers · 414 indexed · h-index 7

Impact in

Papers in

Max Lerchenberger

7 papers receiving 409 citations

Peers

Max Lerchenberger
Comparison fields: 5 of 75
  • Immunology and Allergy 34
  • Immunology 93
  • Hematology 39
  • Nephrology 24
  • Biomaterials 43
Replace Léonie Rouleau with:
Léonie Rouleau Canada
Rosy Eloy France
Sarah M. Haeger United States
Elisa A. Ferrante United States
Claudia Bang Germany
Jean‐Daniel Malcor United Kingdom
Chiara Castellani Italy
Katjuša Mrak‐Poljšak Slovenia
Leigh G. Parkinson Canada
Jennifer N. Orje United States
Max Lerchenberger relative to Léonie Rouleau Canada Léonie Rouleau's profile →
Citations per field
00.5×
Léonie Rouleau · 1×
Citations per year

Countries citing papers authored by Max Lerchenberger

Since Specialization
Citations

This map shows the geographic impact of Max Lerchenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Lerchenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Lerchenberger more than expected).

Fields of papers citing papers by Max Lerchenberger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Lerchenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Lerchenberger. The network helps show where Max Lerchenberger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Max Lerchenberger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Max Lerchenberger Line = papers co-authored together Max Lerchenberger links everyone, so they are left out of the graph.

All Works

7 of 7 papers shown
#Work
1 201930
2 201336
3 201160
4 201134
5 201040
6 2009106
7 2009108

About Max Lerchenberger

Max Lerchenberger is a scholar working on Immunology and Allergy, Critical Care and Intensive Care Medicine, Biochemistry, Nephrology and Neurology, having authored 7 papers that have together received 414 indexed citations. Recurring topics across this work include Cell Adhesion Molecules Research (2 papers), Nanoparticle-Based Drug Delivery (1 paper), Sympathectomy and Hyperhidrosis Treatments (1 paper), Quantum Dots Synthesis And Properties (1 paper), Trauma, Hemostasis, Coagulopathy, Resuscitation (1 paper), Platelet Disorders and Treatments (1 paper), Immune Response and Inflammation (1 paper) and Acute Ischemic Stroke Management (1 paper). The work is most often cited by research in Immunology and Allergy (34 citations), Immunology (93 citations), Hematology (39 citations), Nephrology (24 citations) and Biomaterials (43 citations). Max Lerchenberger has collaborated with scholars based in Germany, Slovakia and Switzerland. Frequent co-authors include Christoph A. Reichel, Markus Rehberg, Péter Bihari, Fritz Krombach, Stefan Zahler, Marc Praetner, Alexander G. Khandoga, Bernd Uhl, Martin Holzer and Fritz Krombach. Their work appears in journals such as Biomaterials, Arteriosclerosis Thrombosis and Vascular Biology, Circulation, Toxicology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026